RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation
NASDAQ:RIGL • US7665597024
Current stock price
29.2 USD
-1.31 (-4.29%)
At close:
29.4 USD
+0.2 (+0.68%)
After Hours:
This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RIGL Profitability Analysis
1.1 Basic Checks
- In the past year RIGL was profitable.
- In the past year RIGL had a positive cash flow from operations.
- In multiple years RIGL reported negative net income over the last 5 years.
- In multiple years RIGL reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 71.46%, RIGL belongs to the best of the industry, outperforming 99.42% of the companies in the same industry.
- RIGL has a better Return On Equity (93.75%) than 99.42% of its industry peers.
- With an excellent Return On Invested Capital value of 23.92%, RIGL belongs to the best of the industry, outperforming 97.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| ROIC | 23.92% |
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RIGL has a better Profit Margin (124.72%) than 98.65% of its industry peers.
- The Operating Margin of RIGL (42.63%) is better than 98.45% of its industry peers.
- Looking at the Gross Margin, with a value of 93.33%, RIGL belongs to the top of the industry, outperforming 94.20% of the companies in the same industry.
- RIGL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.63% | ||
| PM (TTM) | 124.72% | ||
| GM | 93.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
2. RIGL Health Analysis
2.1 Basic Checks
- RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, RIGL has more shares outstanding
- Compared to 5 years ago, RIGL has less shares outstanding
- Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 1.69, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
- With a decent Altman-Z score value of 1.69, RIGL is doing good in the industry, outperforming 63.83% of the companies in the same industry.
- RIGL has a debt to FCF ratio of 0.69. This is a very positive value and a sign of high solvency as it would only need 0.69 years to pay back of all of its debts.
- RIGL's Debt to FCF ratio of 0.69 is amongst the best of the industry. RIGL outperforms 95.16% of its industry peers.
- RIGL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
- RIGL has a Debt to Equity ratio of 0.06. This is comparable to the rest of the industry: RIGL outperforms 40.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.69 | ||
| Altman-Z | 1.69 |
ROIC/WACC2.5
WACC9.56%
2.3 Liquidity
- RIGL has a Current Ratio of 2.42. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of RIGL (2.42) is worse than 71.76% of its industry peers.
- A Quick Ratio of 2.30 indicates that RIGL has no problem at all paying its short term obligations.
- RIGL has a Quick ratio of 2.30. This is in the lower half of the industry: RIGL underperforms 71.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.3 |
3. RIGL Growth Analysis
3.1 Past
- RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 593.62%, which is quite impressive.
- The Revenue has grown by 64.15% in the past year. This is a very strong growth!
- Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 22.06% on average per year.
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
3.2 Future
- RIGL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.44% yearly.
- Based on estimates for the next years, RIGL will show a small growth in Revenue. The Revenue will grow by 6.25% on average per year.
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. RIGL Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 4.48, the valuation of RIGL can be described as very cheap.
- 98.65% of the companies in the same industry are more expensive than RIGL, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of RIGL to the average of the S&P500 Index (26.78), we can say RIGL is valued rather cheaply.
- With a Price/Forward Earnings ratio of 7.05, the valuation of RIGL can be described as very cheap.
- RIGL's Price/Forward Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.45% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.54, RIGL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.48 | ||
| Fwd PE | 7.05 |
4.2 Price Multiples
- 98.84% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
- RIGL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.13 | ||
| EV/EBITDA | 2.71 |
4.3 Compensation for Growth
- The decent profitability rating of RIGL may justify a higher PE ratio.
- RIGL's earnings are expected to decrease with -8.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
5. RIGL Dividend Analysis
5.1 Amount
- No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RIGL Fundamentals: All Metrics, Ratios and Statistics
29.2
-1.31 (-4.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2026-03-03/amc
Earnings (Next)05-04 2026-05-04
Inst Owners90.16%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change6.76%
Market Cap539.62M
Revenue(TTM)294.28M
Net Income(TTM)367.02M
Analysts80
Price Target52.22 (78.84%)
Short Float %20.83%
Short Ratio10.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)28.95%
Min EPS beat(2)-9.57%
Max EPS beat(2)67.46%
EPS beat(4)3
Avg EPS beat(4)168.74%
Min EPS beat(4)-9.57%
Max EPS beat(4)592.43%
EPS beat(8)6
Avg EPS beat(8)228.66%
EPS beat(12)10
Avg EPS beat(12)171.43%
EPS beat(16)13
Avg EPS beat(16)137.97%
Revenue beat(2)1
Avg Revenue beat(2)4.83%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)10.05%
Revenue beat(4)3
Avg Revenue beat(4)10.23%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)19.17%
Revenue beat(8)6
Avg Revenue beat(8)10%
Revenue beat(12)10
Avg Revenue beat(12)7.75%
Revenue beat(16)12
Avg Revenue beat(16)11.69%
PT rev (1m)8.94%
PT rev (3m)12.94%
EPS NQ rev (1m)-5%
EPS NQ rev (3m)9.35%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.83%
Revenue NQ rev (1m)4.24%
Revenue NQ rev (3m)7.25%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)-2.56%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.48 | ||
| Fwd PE | 7.05 | ||
| P/S | 1.83 | ||
| P/FCF | 7.13 | ||
| P/OCF | 7.13 | ||
| P/B | 1.38 | ||
| P/tB | 1.47 | ||
| EV/EBITDA | 2.71 |
EPS(TTM)6.52
EY22.33%
EPS(NY)4.14
Fwd EY14.18%
FCF(TTM)4.1
FCFY14.03%
OCF(TTM)4.1
OCFY14.03%
SpS15.93
BVpS21.2
TBVpS19.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number55.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| ROCE | 30.28% | ||
| ROIC | 23.92% | ||
| ROICexc | 38.21% | ||
| ROICexgc | 42.24% | ||
| OM | 42.63% | ||
| PM (TTM) | 124.72% | ||
| GM | 93.33% | ||
| FCFM | 25.71% |
ROA(3y)20.24%
ROA(5y)1.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.21%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | 0.69 | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | 19.09 | ||
| Cash Conversion | 59.16% | ||
| Profit Quality | 20.61% | ||
| Current Ratio | 2.42 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 1.69 |
F-Score6
WACC9.56%
ROIC/WACC2.5
Cap/Depr(3y)409.8%
Cap/Depr(5y)265.74%
Cap/Sales(3y)4.35%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)64.15%
Revenue growth 3Y34.78%
Revenue growth 5Y22.06%
Sales Q2Q%21.19%
Revenue Next Year-3.09%
Revenue Next 2Y4.53%
Revenue Next 3Y6.64%
Revenue Next 5Y6.25%
EBIT growth 1Y418.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.59%
EBIT Next 3Y32.03%
EBIT Next 5YN/A
FCF growth 1Y143.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y140.4%
OCF growth 3YN/A
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
What is the profitability of RIGL stock?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the financial health for RIGL stock?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.
What is the earnings growth outlook for RIGEL PHARMACEUTICALS INC?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to decline by -36.48% in the next year.